Slide 1: Extracorporeal Clearance of Tumor-Secreted Exosomes; An Adjunct Strategy to Improve Cancer Treatment Outcomes
JIM JOYCE CHAIRMAN, CEO EXOSOMES 2014 September 18 & 19, 2014 San Diego, California Extracorporeal Clearance of Tumor - Secreted Exosomes ; An Adjunct Strategy to Improve Cancer Treatment Outcomes
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced ; market acceptance of the A e thlon ADAPT™ system, t
Slide 3: We Create Targeted Therapeutic Devices to Address Infectious Disease and Cancer
We Create Targeted Therapeutic Devices to Address Infectious Disease and Cancer
Slide 4: 2005 An Accidental Journey Into The Exosome Field
2005 An Accidental Journey Into The Exosome Field
Slide 5: Diagnostics and Therapeutics 2014
DIAGNOSTICS THERAPEUTICS 2014
Slide 6: A "Liquid Biopsy" Organization
A “Liquid Biopsy” Organization
Slide 7: Lectin-based Liquid Biopsy Platform
• Launched in November 2013 • Lectin - based “Liquid Biopsy” Platform • Oncology Validations – Bladder, Breast, Colorectal, Glioblastoma , Metastatic Melanoma, Ovarian, and Pancreatic Cancer • Chief Scientific Officer – Dr. Douglas Taylor
Slide 8: Cancer Therapy
CANCER THERAPY aethion/@)
Slide 9: An Adjunct Strategy to Eliminate Circulating Tumor Exosomes Without Added Drug Toxicity
An Adjunct S trategy to Eliminate C irculating Tumor Exosomes W/O added drug toxicity
Slide 10: The Aethlon Hemopurifier: Rapid elimination of tumor-secreted exosomes
The A e thlon Hemopurifier® Rapid elimination of tumor - secreted exosomes
Slide 11: Tumor-Secreted Exosomes
Tumor - Secreted Exosomes Extracellular Vesicles or Circulating Microvesicles
Slide 12: Slide 12
Slide 13: Tumor-Secreted Exosome Validations
Tumor - Secreted Exosome Validations
Slide 14: Exosome Validations
EXOSOME VALIDATIONS BREAST OVARIAN COLORECTAL LYMPHOMA MELANOMA
Slide 15: Why Target Tumor-Secreted Exosomes?
Why Target Tumor - Secreted Exosomes ?
Slide 16: Extracellular Vesicles: Emerging Targets for Cancer Therapy
May, 2014 Trends in Molecular Medicine "Extracellular Vesicles: Emerging Targets for Cancer Therapy"
Slide 17: Tumor-Secreted Exosomes
Tumor - Secreted Exosomes • Trigger apoptosis of immune c ells • Contribute to drug and chemotherapy resistance • Promote angiogenesis • Seed the creation and spread of metastasis • Exosome load correlates with stage of cancer
Slide 18: Exosomes Transport Biopharmaceutical Industry Targets
Exosomes Transport Biopharmaceutical Industry Targets
Slide 19: Programmed Cell Death & Ligand (PD-1/PDL-1)
Programmed Cell Death 1 & Ligand (PD - 1/ PDL - 1) Merck : Lambrolizumab /MK - 3475 (anti - PD - 1 mAb ) Bristol - Myers Squibb: Nivolumab /BMS - 936558 (anti - PD - 1 mAb ) CureTech / Teva : Pidilizumab /CT - 011 (anti - PD - 1 mAb ) Roche /Genentech: MPDL3280A (anti - PD - L1 mAb ) Medimmune/Astra
Slide 20: CTLA-4
CTLA - 4 Bristol - Myers Squibb: Ipilimumab / Yervoy ® (anti - CTLA - 4 mAb ) Medimmune /Pfizer: Tremelimumab /CP - 675 - 206 (anti - CTLA - 4 mAb )
Slide 21: Hepatocyte Growth Factor & Receptor (Met)
Hepatocyte growth factor (HGF) & Receptor (Met ) Amgen : Rilotumumab /AMG 102 (anti - HGF mAb ) Genentech /Roche: Onartuzumab /OA - 5D (anti - Met mAb ) Aveo : Ficlatuzumab /AV - 299 (anti - HGF mAb ) Amgen : AMG 337 (MET TKI) Eli Lilly: LY - 2875358 (anti - Met mAb ) ArQule : Tivantinib /ARQ 197 (M
Slide 22: Fibroblast Growth Factor, Galectin3 and B-raf
Fibroblast growth factor (FGF) Novartis : Dovitinib /TK1285 (FGFR, VEGFR & PDGF TKI) Galectin3 Galectin Therapeutics: GM - CT - 01 & GR - MD - 02 ( galectin antagonists) B - raf GlaxoSmithKline : Tafinlar ™/ Dabrafenib (B - raf kinase inhibitor) Genentech : Zelboraf ®/ Vemurafenib (B - raf kinase in
Slide 23: Epidermal Growth Factor Receptor (EGFR)
Epidermal Growth Factor Receptor (EGFR) Genentech : Tarceva ®/ Erlotinib (EGFR TKI) Bristol - Myers Squibb & Eli Lilly: Cetuximab /Erbitux (anti - EGFR mAb ) Amgen : Vectitbix / Panitumumab (anti - EGFR mAb ) Boehringer Ingelheim : Gilotrif ™/ Afatinib (EGFR/HER2 TKI )
Slide 24: HER2 and CD20
HER2 Genentech : Herceptin®/ Trastuzumab (anti - HER2 mAb ) Genentech : Kadcyla ®/Ado - trastuzumab emtansine (anti - HER2 mAb linked to DM1 drug) Genentech : Perjeta ®/ Pertuzimab (anti - HER2 mAb ) GlaxoSmithKline: Tykerb / Lapatinib (dual TKI against HER2 and EGFR) CD20 Biogen Idec & Genentech: R
Slide 25: P-glycoprotein and VEGF
P - glycoprotein Novartis : Valspodar /PSC - 833 (P - glycoprotein inhibitor). Vascular endothelial growth factor (VEGF) & Receptor (VEGFR ) Genentech /Roche: Avastin ®/ Bevacizumab (anti - VEGF mAb ) Eli Lilly: Cyramza ™ / Ramucirumab (anti - VEGFR2 mAb ) Exelixis /GlaxoSmithKline: Foretnib /XL880/
Slide 26: Will the Elimination of Circulating Tumor-Secreted Exosomes Improve Outcomes?
Will the Elimination of Circulating Tumor - Secreted Exosomes Improve Outcomes?
Slide 27: By the Way!
BY THE WAY!
Slide 28: The Aethlon Hemopurifier
The A e thlon Hemopurifier®
Slide 29: Hemopurifier Therapy
Hemopurifier ® Therapy • FDA approved IDE to initiate U.S. studies • Administered in ~100 human treatment experiences – HIV and Hepatitis C (HCV) Infected Individuals – Broad - spectrum in vitro data against category “A” bioterror and pandemic threats, including ebola
Slide 30: The Aethlon Hemopurifier: Currently Preparing Submission of Cancer IDE
The A e thlon Hemopurifier® Currently Preparing Submission of Cancer IDE
Slide 31: Does the Elimination of Circulating Tumor-Secreted Exosomes Improve Outcomes?
Does the Elimination of Circulating Tumor - Secreted Exosomes Improve Outcomes?
Slide 32: We Create Targeted Therapeutic Devices to Address Infectious Disease and Cancer
We Create Targeted Therapeutic Devices to Address Infectious Disease and Cancer
Slide 33: Save Lives
Save Lives